Details of the Drug

General Information of Drug (ID: DM9R5J6)

Drug Name

Tezepelumab

Indication

Disease Entry	ICD 11	Status	REF
Severe asthma	CA23	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

ADMET Property

Bioavailability: The bioavailability of drug is 77% [2]
Clearance: The clearance of drug is 0.17 L/day [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 26 days [2]
Metabolism: The drug is metabolized via various proteolytic enzymes throughout the body [2]
Vd: The volume of distribution (Vd) of drug is 3.9 L [2]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Thymic stromal lymphopoietin (TSLP)	TTHMW3T	TSLP_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Severe asthma

ICD Disease Classification

CA23

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Thymic stromal lymphopoietin (TSLP)	DTT	TSLP	8.89E-01	0.3	0.26

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761224.
2	FDA Approved Drug Products: TEZSPIRE (tezepelumab-ekko) injection
3	Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946.